Objectives. To investigate whether the therapeutic response of rheumatoid arthritis (RA) patients to -penicillamine is associated with polymorphisms in genes of the glutathione S-transferase (GST ) supergene family.
Early and reliable identification of rheumatoid arthritis
Although a wide range of drugs, with varying mechanisms of action, are available for use in the treatment of (RA) patients who are at risk of poor long-term outcome would be clinically useful if it allowed more aggressive RA, selection is often problematic because of adverse reactions or lack of response. Accordingly, drug treattreatment to be appropriately targeted. There has been considerable interest, therefore, in the identification of ment in RA is often pragmatic and it is not unusual for an individual patient to be prescribed a range of different genetic markers of clinical outcome. Much of this work has been focused on genes of the HLA system. The drugs during the course of the disease. The identification of markers that indicate whether or not a particular HLA-DR genotype, and specifically the presence of the 'RA shared epitope', a conserved amino acid sequence drug is likely to be beneficial would therefore have important consequences for treatment. (QKRAA or QRRAA) in positions 70-74 of the DRB1 molecule, has been related to disease severity [1] . It is
The enzymes of the cytochrome P450 (CYP) and glutathione S-transferase (GST ) supergene families utilsuggested that resistance to drug therapy is a possible mechanism for this effect [2] , although the influence of ize a wide range of drugs and chemicals as substrates, suggesting that they may mediate individual responses HLA status on the response to drugs in RA remains unclear. Thus, Ten Wolde et al. [3] reported that HLA to drug therapy. There are little data on the influence of these enzyme families on the metabolism of drugs typing is not helpful in predicting the therapeutic response to parenteral gold therapy. This is in contrast used to treat RA, although a recent study demonstrated that the activity of the glucocorticoid-inducible CYP3A4 to the reported association of gold toxicity with HLA-DR3 [4] . There are little data on other genes that might in RA patients was not altered by various anti-rheumatic agents and substrates of this isoenzyme [5] . GST influence the therapeutic response in RA.
enzymes catalyse the detoxification of a wide range of electrophiles by catalysing their conjugation with chemicals, including products of oxidant stress such as sent those completing 6 months of -penicillamine therapy. The original study group was 86 patients, of lipid and DNA hydroperoxides [6 ] . Polymorphisms have been identified in genes of the mu (GSTM1, whom four (4.6%) dropped out because of side-effects and one (1.2%) was non-compliant. Patients were GSTM3), theta (GSTT1) and pi (GSTP1) families [7] , and there is evidence that some allelic variants are assessed using the Stoke Index, a validated composite algorithm designed to give a global measure of disease associated with differences in detoxification efficiency. In several cancers, resistance to chemotherapy has been activity in RA, which is sensitive to response to drug treatment [13, 15] . The Stoke Index grades disease associated with increased GST activity in tumour cells [8] .
activity on the basis of the Ritchie articular index, proximal interphangeal joint synovitis (PIP) score, durGeneration of reactive oxygen species (ROS) is a marked feature of the inflammatory response in RA, ation of morning stiffness, ESR and CRP. The algorithm consists of a 17-point scale with 1-3 representing minand we have suggested that the ability to metabolize products of ROS may influence long-term outcome.
imal disease activity, 4-7 mild, 8-11 moderate and 12-17 severe. Thus, our preliminary data indicate that polymorphisms in GST genes may have an influence on incidence and
In order to determine whether the -penicillaminetreated patients represented a typical group of RA disease outcome in RA [9] . We propose that the ability to detoxify products of oxidant stress may also influence patients, we also compared the GST frequencies of the -penicillamine-treated patients with a much larger the response to certain drug therapies. In the present study, we examined the response to -penicillamine, group of RA patients untreated with this drug (n = 194), obtained from a study investigating the assowhich has been suggested to act as an antioxidant by inhibiting lipid peroxidation [10] , as well as demonstratciation between GST polymorphisms and disease outcome [16 ] . There were no significant differences between ing hydroxyl radical scavenging activity in vitro [11] . It has also been shown to increase levels of erythrocyte the two groups for any of the GST genotypes (data not shown). glutathione in RA patients [12] . We speculate that in RA patients with certain GST polymorphisms (e.g.
Genotype data in the -penicillamine-treated RA patients were also compared with those in 577 Northern GSTM1 null, GSTT1 null, GSTM3AA), there is a reduced capacity to detoxify the products of oxidative European Caucasians resident in North Staffordshire. This group comprised 277 men and 300 women with a stress produced by the inflammatory process, and that increased oxidation of -penicillamine occurs which mean age of 70 yr. Patients with inflammatory pathologies such as ulcerative colitis, diabetes or asthma renders it less effective. We have tested this view by investigating the association between GST polymorphwere excluded, although 30% of these controls suffered diseases including varicose veins, hernias, haemorrhoids, isms and response to treatment as assessed by the Stoke Index [13] .
mild iron deficiency anaemia, mild hyperlipidaemia and benign ovarian cysts. The remainder suffered tension headaches (25%), benign skin papillomas (20%), benign
Patients and methods breast lumps (5%), or cerebrovascular accidents (20%). A study group of 81 patients (38 male, 43 female)
Outcome measures meeting the 1987 ACR diagnostic criteria [14] for RA were selected. The mean age was 52.6 yr (.. 9.8) and
The therapeutic response at 6 months was defined using the Stoke Index. Non-responders to therapy were the mean disease duration 6.1 yr (.. 5.8). Of this group, 48 patients (59.2%) were rheumatoid factor posidefined as those patients who following 6 months treatment with -penicillamine achieved either no tive and 13 patients (16%) had rheumatoid nodules. All patients were unrelated Northern European Caucasians change in their Stoke Index category or entered a worse category. from North Staffordshire started on -penicillamine monotherapy (non-steroidal anti-inflammatory drugs Genotyping permitted ) on clinical grounds [ Á 6 painful joints and erythrocyte sedimentation rate (ESR) >30 mm/h or GST genotypes were identified in leucocyte DNA from whole blood collected in EDTA. The GSTM1 null, A, C-reactive protein (CRP) >20 mg/l ]. All patients were assessed prior to therapy and 6 months after starting B and AB genotypes were identified using an amplification refractory mutation system (ARMS )-based poly--penicillamine according to our standard departmental clinical protocol. Treatment commenced with 250 mg merase chain reaction (PCR) approach with primer sets to intron 6/exon 7 and exon 4/exon 5. The assay daily, increasing at 4 week intervals by increments of 125 mg until either response occurred or the maximum identifies GSTM1*A/GSTM1*B heterozygotes and subjects with the GSTM1 A and GSTM1 B phenotypes. It tolerated dose was achieved (maximum 750 mg daily). All patients were advised to take the -penicillamine as does not distinguish the GSTM1*0/GSTM1*A and GSTM1*A/GSTM1*A genotypes or the equivalent a single morning dose prior to the intake of food and there was no concomitant oral iron therapy. Patients GSTM1 B genotypes [17, 18] . The GSTM3 AA, AB and BB genotypes were identified by amplifying the were reviewed monthly in our drug monitor clinics in order to identify any problems of toxicity and monitor exon 6/7 regions of GSTM3*A and GSTM3*B, and differentiating GSTM3*A from GSTM3*B by digestion compliance with therapy. The 81 patients studied repre-with Mnl1 to identify the three-base deletion in intron GSTM1*0/GSTM3*A haplotype was also significantly higher (OR 7.63, 95% CI 1.84-31.72, P = 0.0052) in the 6 of GSTM3*B [19] . The GSTP1 AA, AB and BB genotypes were identified in leucocyte DNA after PCR non-responders (72.2%) than responders (35.6%), although no significant effect of GSTM3 AA alone was amplification using primers to exon 5 as described by Harries et al. [20] . The resulting 176 bp fragment was seen. Furthermore, all of the non-responders with the GSTM1 null genotype were GSTM3 AA positive, whilst digested with Alw261 to identify the A-G transition as position 1578 in GSTP1*B. GSTP1*A was refractory to only 70% of the GSTM1 null responders possessed the GSTM3 AA genotype. There was no significant differdigestion whilst GSTP1*B gave fragments of 91 and 85 bp. The GSTT1 null and GSTT1 A expressing subence between the two groups studied in the frequency of other GST genotypes. No significant correlation jects were also identified using PCR [21] .
between GST genotype and rheumatoid factor positivity Statistical analysis was found. Logistic regression was used so that any effect of the genotype on response could be corrected for age, sex, Discussion disease duration and initial Stoke Index. There was no significant difference between the responders and the The data presented suggest that RA patients with the GSTM1 null genotype are significantly more likely than non-responders for these factors individually, but they were included in the analysis in the case of a compound patients homo-or heterozygous for the GSTM1*A or GSTM1*B alleles to respond poorly to -penicillamine effect. The odds ratio (OR) was calculated from the exponential function of the regression coefficient as during the first 6 months of treatment. Moreover, possession of the GSTM1*0/GSTM3*A haplotype further described by Altman [22] . Estimates of the parameters associated with the genotype are expressed in terms of increases the likelihood of non-response compared to patients without this haplotype. The overall GST geno-OR and the associated 95% confidence interval (CI ).
type distribution in the -penicillamine-treated patients appears to be representative of the RA patient populaResults tion in North Staffordshire since there were no significant differences in the genotype frequencies of these Eighteen of the 81 patients did not respond to -penicillamine at 6 months according to the definition patients and a larger group of RA patients not treated with the drug. given above. The characteristics of the non-responders and the responders are summarized in Table 1 . There A logistic regression model was used to correct for the effect of possible confounding factors such as age, was no significant difference in age, disease duration, rheumatoid factor positivity or Stoke Index prior to gender and disease duration. The analysis does not exclude the possibility that the effect is mediated through treatment between the two groups. The GST genotype frequencies in the responders and non-responders are another gene in linkage disequilibrium with GSTM1 and/or GSTM3, or perhaps is due to an unrelated gene shown in Table 2 . The frequencies in all the -penicillamine-treated patients are also reported and compared to encoding a drug-metabolizing enzyme which can be modulated in association with the GSTM1 null genoa control group of non-RA patients resident in North Staffordshire (n = 577). There were no significant type. For example, the GSTM1 null genotype has been shown to be associated with high inducibility of the differences between GST genotype frequencies in the -penicillamine-treated RA group and the control cytochrome P450 isoenzyme CYP1A1 [23] .
In this study, we have no information on the activity non-RA group.
Using logistic regression analysis, we found that in -of other enzyme systems, although the association of GSTM1 null with a poor response appears to be linked penicillamine-treated patients the frequency of GSTM1 null was significantly higher in the non-responders than with the presence of the GSTM3 AA genotype. GSTM3 AA alone was not associated with response. A similar the responders (72.2% vs 47.6%: OR 3.94, 95% CI 1.07-14.45, P = 0.039). The frequency of the association between these genotypes was found in a study of patients with multiple basal cell carcinoma, T 1. Characteristics of responders and non-responders to where GSTM3 AA alone was not associated with -penicillamine increased risk of multiple tumours, but conferred increased risk in combination with GSTM1 null [24] .
Non-responders Responders
Co-ordinated expression of the mu class (i.e. GSTM1, GSTM1 genotypes [25] . Although the mechanism for (yr) (..)
this is unclear, it may be related to the finding that GSTM3*A, suggesting that those with either a chemotherapeutic agents in epithelial ovarian cancer and GSTM1 genotypes. Thus, in women with this GSTM1*0/GSTM3*A or GSTM1*B/GSTM3*A haplotype will express less GSTM3 than those with the cancer, GSTM1 null was associated with a failure to respond to platinum-based therapy and consequently GSTM1*A/GSTM3*B haplotype. Thus, it has been suggested that assessment of the contribution of GSTM1 significantly poorer outcome. Resistance to platinumbased treatment has been closely associated with cellular genotypes as susceptibility markers for disease risk needs to take account of interactions with GSTM3 [18] . The glutathione levels, although it is not known whether our observations reflect an influence of GST allelic variants results of this study now indicate that interactions between these mu class genes may also be important in on the expression of enzymes involved with glutathione synthesis [29, 30] . determining the response to -penicillamine.
The mechanism for this effect is unknown, although Although these mechanisms are purely speculative at present, the influence of GST polymorphisms in RA we have speculated that it is related to the apparent importance of the mu class GST in the detoxification of appear to be important in terms of disease outcome and the response to -penicillamine. At present, we do not lipid hydroperoxides, alkenals, DNA hydroperoxides and other products of oxidative stress. Thus, RA feel that there is sufficient evidence to recommend pretreatment genotyping of RA patients in routine clinical patients lacking the GSTM1 enzyme and also possessing lower levels of GSTM3 will have a reduced capacity to practice. More work is required to confirm these finding and to determine whether the therapeutic response to deal with these potentially cytotoxic chemicals. Consequently, since -penicillamine may act as an antiother disease-modifying anti-rheumatic drugs relates to the GST genotype. oxidant under some circumstances [10, 11, 27] , it is possible that higher levels of ROS-derived products in patients with the GSTM1*0/GSTM3*A haplotype result
